On November 22, Kronos Bio Board Approved Approximately 83% Reduction In Its Workforce; Norbert Bischofberger Resigns As President And CEO, Effective December 3, 2024 - Filing
On November 22, Kronos Bio Board Approved Approximately 83% Reduction In Its Workforce; Norbert Bischofberger Resigns As President And CEO, Effective December 3, 2024 - Filing
On November 22, 2024, Deborah Knobelman, the Company's Chief Financial Officer and Chief Operating Officer, was appointed to serve as President and Interim Chief Executive Officer, effective December 3, 2024. Knobelman will also continue to serve as the Company's Chief Financial Officer and Chief Operating Officer.The workforce reduction is expected to be substantially completed on December 31, 2024.
預計到2024年12月31日，裁員工作將基本完成。
In connection with the reduction in workforce, the Company expects to incur a charge of approximately $3.7 million relating to the cash-based expense of the employee severance, benefits, and related costs.
關於裁員，預計公司將產生大約370萬美元的費用，涉及員工遣散費、福利及相關費用。
The Company anticipates payments associated with the workforce reduction will be substantially complete by the end of the first quarter of 2025.
公司預計與裁員相關的付款將在2025年第一季度末基本完成。
On November 22, 2024, Deborah Knobelman, the Company's Chief Financial Officer and Chief Operating Officer, was appointed to serve as President and Interim Chief Executive Officer, effective December 3, 2024. Knobelman will also continue to serve as the Company's Chief Financial Officer and Chief Operating Officer.
2024年11月22日，公司首席財務官及首席運營官德博拉·諾貝爾曼被任命爲總裁及臨時首席執行官，自2024年12月3日起生效。諾貝爾曼還將繼續擔任公司的首席財務官及首席運營官。
譯文內容由第三人軟體翻譯。
